Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study

The Eighth Edition <scp>AJCC</scp> Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians · 2017 · 6.5K citations · Full text

Medicine, Cancer Biology, Oncology +17

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

Laurent Beaugerie, Nicole Brousse, Anne‐Marie Bouvier et al. · The Lancet · 2009 · 1.1K citations

Medicine, Hematology, Immunology +11

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Jean‐Frédéric Colombel, Bruce E. Sands, Paul Rutgeerts et al. · Gut · 2016 · 803 citations · Full text

Pharmacy, Pharmacology, Clinical Epidemiology +10

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

Magali Lemaître, Julien Kirchgesner, A. Rudnichi et al. · JAMA · 2017 · 558 citations · Full text

Medicine, Oncology, Pharmacology +13

Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease

Millie D. Long, Christopher F. Martin, Clare A. Pipkin et al. · Gastroenterology · 2012 · 521 citations · Full text

Medicine, Dermatology, Oncology +14